比依股份(603215.SH):理湃光晶已形成完整的AR幾何光波導顯示鏡片的專有技術和獨創工藝
格隆匯6月25日丨比依股份(603215.SH)在互動平臺表示,理湃光晶在AR智能眼鏡領域,已形成完整的AR幾何光波導顯示鏡片的專有技術和獨創工藝。其依託領先的幾何光波導“二維擴瞳”技術和“分子鍵合”工藝開發的AR幾何光波導二維波導鏡片,面向輕量消費級AR眼鏡,爲消費端帶來更加輕薄、透亮、高清畫質的AR光波導產品和解決方案,目前已應用在AR+AI智能眼鏡中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.